Cardiovascular and Renal Outcomes with Ertugliflozin by Baseline Use of Renin-Angiotensin-Aldosterone System Inhibitors or Diuretics, Including Mineralocorticoid Receptor Antagonist: Analyses from the VERTIS CV Trial

Cardiovascular and Renal Outcomes with Ertugliflozin by Baseline Use of Renin-Angiotensin-Aldosterone System Inhibitors or Diuretics, Including Mineralocorticoid Receptor Antagonist: Analyses from the VERTIS CV Trial

Introduction: VERTIS CV was a placebo-controlled cardiovascular (CV) outcome trial evaluating the sodium-glucose cotransporter 2 inhibitor ertugliflozin in patients with type 2 diabetes and established atherosclerotic CV disease. The aim of the current analyses was to evaluate VERTIS CV c...

Full description

Saved in:
Bibliographic Details
Main Authors: David Z.I. Cherney, Robert Frederich, Richard E. Pratley, Francesco Cosentino, Samuel Dagogo-Jack, Annpey Pong, Ira Gantz, Nilo B. Cater, James P. Mancuso, Urszula Masiukiewicz, Christopher P. Cannon
Format: Article
Language:English
Published: Karger Publishers 2025-01-01
Series:Kidney Diseases
Online Access:https://karger.com/article/doi/10.1159/000543162
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://karger.com/article/doi/10.1159/000543162

Similar Items